Articles related to COVID-19

Recent research from Brown University suggests that the SARS-CoV-2 spike protein could interfere with cancer treatment efficacy by affecting the p53 gene’s ability to suppress tumor growth and repair DNA.

“In light of recent findings, it is crucial to evaluate the implications of modified mRNA in therapeutic uses, particularly its role in immune response and potential cancer progression.”

In a recent phase 2–3 trial, nirmatrelvir–ritonavir did not significantly shorten the time to COVID-19 symptom resolution compared to placebo, yet it demonstrated a trend towards reduced hospitalization and death rates, emphasizing the importance of tailored treatment strategies.

The study highlights the persistence of immune imprinting in COVID-19 vaccinated individuals, where the immune response remains skewed towards the original virus, even after booster vaccinations for new variants.

Pemgarda™ emerges as a pivotal development in COVID-19 prophylaxis, particularly for patients with moderate to severe immune compromise, providing a new layer of defense for those less responsive to vaccination.

In a recent study, vaccinated COVID-19 patients showed a 70% mortality rate when hospitalized, surpassing the 37% rate in unvaccinated patients, challenging assumptions about vaccine efficacy in severe cases.